Not a classical antidepressant. Not a psychedelic.

A New Frontier.

Protagenic is a neuropeptide medicine company focused entirely on the biology of modulating stress responses. No direct action on serotonin. No sedation. No psychedelic-assisted experiences requiring specialized clinics and intensive monitoring. A targeted, mechanistically precise approach to the brain's own stress-control chemistry—whose action will have rapid onset and without the normal side effects that impede success.

Learn More

Stats Bar

~30M

Americans with stress disorders receiving care do not meet their goals*

20+

Years of foundational TCAP research

1st

First-in-class neuropeptide medicine

PH2

Ph1 study complete for PT00114 and entering Ph2 clinical program
1) Norris T., et. al. Early Release of Selected Estimates Based on Data From the 2023 National Health Interview Survey, National Center for Health Statistics, U.S. Dept of Healthand Human Services; 2) Anxiety Disorders - Facts & Statistics, ADAA, 2024; 3) PTSD statistics 2024, The Checkup by SingleCare; 4) SAMHSA Annual National Survey on Drug Useand Health, July 30, 2024, U.S. Dept of Health and Human Services.
Close ✕

Breaking the Stress Feedback Loop

Stress overdrive is central to the onset and progression of many neuropsychiatric disorders. Teneurin C-terminal Associated Peptides (TCAPs) comprise a neuropeptide system that has evolved over millions of years across species (ranging from fish to humans) as a primary regulator of the stress response. It counteracts this loop at the cellular level in the brain.

The science 
A flickering drawn brain with a line that makes several loops.

TCAP-1 builds stress resilience

Acute event triggers stress response

TCAP-1 quiets the threat response

Stress system overreacts and becomes hypersensitive

TCAP-1 resets the feedback loop

Stress regulation fails; diseases and neurobiological changes emerge

arrow to the left
arrow to the right

Who we are

Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.
Garo H. Armen, Ph.D.

Garo H. Armen, Ph.D.

Chairman of the Board
Learn More
Garo H. Armen, Ph.D.

Garo H. Armen, Ph.D.

Executive Chairman
Learn More
Jennifer Buell, Ph.D.

Jennifer Buell, Ph.D.

Director
Learn More
Bill Nichols

Bill Nichols

President
Learn More
Timothy Wright

Timothy Wright

Director
Learn More
Andrew Slee, Ph.D.

Andrew Slee, Ph.D.

Chief Development Officer
Learn More
Brian J. Corvese

Brian J. Corvese

Director
Learn More
Robert B. Stein, M.D., Ph.D.

Robert B. Stein, MD, Ph.D.

Chief Medical Officer
Learn More
Lauren Mueller, Ph.D.

Lauren Mueller, Ph.D.

Associate Director of Preclinical Development
Learn More

Our progress

Protagenic Therapeutics Completes Phytanix Separation, Strengthens Balance Sheet and Repositions the Company Around PT00114

Read now ↗

Protagenic Therapeutics Upgrades from OTC Pink to OTCQB Venture Market

Read now ↗

Results from Phase 1 Multiple-Dose Study of PT00114

Read now ↗

Protagenic Therapeutics Advances PT00114 into Multiple-Dose Phase 1 Trial; Positioning for Phase 2 in Stress & Mood Disorders

Read now ↗

Protagenic Therapeutics Receives $3.1 Million from Recent Warrant Activity

Read now ↗